296 related articles for article (PubMed ID: 26065334)
1. Investigation of ligand selectivity in CYP3A7 by molecular dynamics simulations.
Fan JR; Zheng QC; Cui YL; Li WK; Zhang HX
J Biomol Struct Dyn; 2015; 33(11):2360-7. PubMed ID: 26065334
[TBL] [Abstract][Full Text] [Related]
2. Structural and energetic analysis to provide insight residues of CYP2C9, 2C11 and 2E1 involved in valproic acid dehydrogenation selectivity.
Bello M; Mendieta-Wejebe JE; Correa-Basurto J
Biochem Pharmacol; 2014 Jul; 90(2):145-58. PubMed ID: 24794636
[TBL] [Abstract][Full Text] [Related]
3. Helices F-G are important for the substrate specificities of CYP3A7.
Torimoto N; Ishii I; Toyama K; Hata M; Tanaka K; Shimomura H; Nakamura H; Ariyoshi N; Ohmori S; Kitada M
Drug Metab Dispos; 2007 Mar; 35(3):484-92. PubMed ID: 17178770
[TBL] [Abstract][Full Text] [Related]
4. Structural Basis for the Diminished Ligand Binding and Catalytic Ability of Human Fetal-Specific CYP3A7.
Sevrioukova IF
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072457
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Species-Selectivity of Human, Mouse and Rat Cytochrome P450 1A and 2B Subfamily Enzymes using Molecular Modeling, Docking and Dynamics Simulations.
Karthikeyan BS; Suvaithenamudhan S; Akbarsha MA; Parthasarathy S
Cell Biochem Biophys; 2018 Jun; 76(1-2):91-110. PubMed ID: 28353142
[TBL] [Abstract][Full Text] [Related]
6. In vitro and pharmacophore insights into CYP3A enzymes.
Ekins S; Stresser DM; Williams JA
Trends Pharmacol Sci; 2003 Apr; 24(4):161-6. PubMed ID: 12707001
[TBL] [Abstract][Full Text] [Related]
7. DR-predictor: incorporating flexible docking with specialized electronic reactivity and machine learning techniques to predict CYP-mediated sites of metabolism.
Huang TW; Zaretzki J; Bergeron C; Bennett KP; Breneman CM
J Chem Inf Model; 2013 Dec; 53(12):3352-66. PubMed ID: 24261543
[TBL] [Abstract][Full Text] [Related]
8. Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1.
Jerabek P; Martinek V; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():25-32. PubMed ID: 23353840
[TBL] [Abstract][Full Text] [Related]
9. Structural and dynamic basis of human cytochrome P450 7B1: a survey of substrate selectivity and major active site access channels.
Cui YL; Zhang JL; Zheng QC; Niu RJ; Xu Y; Zhang HX; Sun CC
Chemistry; 2013 Jan; 19(2):549-57. PubMed ID: 23180418
[TBL] [Abstract][Full Text] [Related]
10. Computational insights into the different catalytic activities of CYP2A13 and CYP2A6 on NNK.
Xu Y; Shen Z; Shen J; Liu G; Li W; Tang Y
J Mol Graph Model; 2011 Sep; 30():1-9. PubMed ID: 21680215
[TBL] [Abstract][Full Text] [Related]
11. Importance of hydrophobic parameters in identifying appropriate pose of CYP substrates in cytochromes.
Ramesh M; Bharatam PV
Eur J Med Chem; 2014 Jan; 71():15-23. PubMed ID: 24269512
[TBL] [Abstract][Full Text] [Related]
12. Exploration of the binding of proton pump inhibitors to human P450 2C9 based on docking and molecular dynamics simulation.
Shi R; Li J; Cao X; Zhu X; Lu X
J Mol Model; 2011 Aug; 17(8):1941-51. PubMed ID: 21120554
[TBL] [Abstract][Full Text] [Related]
13. Homology modeling and docking studies of FabH (β-ketoacyl-ACP synthase III) enzyme involved in type II fatty acid biosynthesis of Chlorella variabilis: a potential algal feedstock for biofuel production.
Misra N; Patra MC; Panda PK; Sukla LB; Mishra BK
J Biomol Struct Dyn; 2013 Mar; 31(3):241-57. PubMed ID: 22830394
[TBL] [Abstract][Full Text] [Related]
14. Comparative Study of Binding Pockets in Human CYP1A2, CYP3A4, CYP3A5, and CYP3A7 with Aflatoxin B1, a Hepato-Carcinogen, by Molecular Dynamics Simulation & Principal Component Analysis.
Saba N; Seal A
Curr Drug Metab; 2022; 23(7):521-537. PubMed ID: 35850656
[TBL] [Abstract][Full Text] [Related]
15. Computational insights into the different catalytic activities of CYP3A4 and CYP3A5 toward schisantherin E.
Xue Y; Li J; Wu Z; Liu G; Tang Y; Li W
Chem Biol Drug Des; 2019 May; 93(5):854-864. PubMed ID: 30637977
[TBL] [Abstract][Full Text] [Related]
16. Human cytochrome P450 3A7 has a distinct high catalytic activity for the 16alpha-hydroxylation of estrone but not 17beta-estradiol.
Lee AJ; Conney AH; Zhu BT
Cancer Res; 2003 Oct; 63(19):6532-6. PubMed ID: 14559847
[TBL] [Abstract][Full Text] [Related]
17. In silico characterization of binding mode of CCR8 inhibitor: homology modeling, docking and membrane based MD simulation study.
Gadhe CG; Balupuri A; Cho SJ
J Biomol Struct Dyn; 2015; 33(11):2491-510. PubMed ID: 25617117
[TBL] [Abstract][Full Text] [Related]
18. CYP3A4 and CYP3A7-mediated carbamazepine 10,11-epoxidation are activated by differential endogenous steroids.
Nakamura H; Torimoto N; Ishii I; Ariyoshi N; Nakasa H; Ohmori S; Kitada M
Drug Metab Dispos; 2003 Apr; 31(4):432-8. PubMed ID: 12642469
[TBL] [Abstract][Full Text] [Related]
19. Molecular Dynamics Simulation Framework to Probe the Binding Hypothesis of CYP3A4 Inhibitors.
Kiani YS; Ranaghan KE; Jabeen I; Mulholland AJ
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31510073
[TBL] [Abstract][Full Text] [Related]
20. Computational Investigation of Ligand Binding to the Peripheral Site in CYP3A4: Conformational Dynamics and Inhibitor Discovery.
Du H; Li J; Cai Y; Zhang H; Liu G; Tang Y; Li W
J Chem Inf Model; 2017 Mar; 57(3):616-626. PubMed ID: 28221037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
